XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) Stock Price
XTLBStock
$2.60−48.20%52W
Market Cap$6.39M
P/E—
PEG Ratio2.27
Div yield—
Beta0.76
XTLB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-40.71%
Price vs S&P 500 (4W)-8.37%
PEG Ratio2.27
VGM Score30.81
XTLB Earnings Surprise History
Q2 15-0.02est. 0.00
Q3 15-0.02est. -0.20
Q4 15-0.06est. 0.00
Q1 16-0.04est. 0.00
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares | — | — | D | $2.60 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About XTL Biopharmaceuticals Ltd. American Depositary Shares
XTL Biopharmaceuticals develops therapeutics for unmet medical needs in autoimmune and oncology indications. Its lead candidate, hCDR1, is a synthetic peptide in Phase II development for systemic lupus erythematosus and Sjögren's syndrome. The company is also advancing rHuEPO, a recombinant human erythropoietin, to extend survival in multiple myeloma patients.